Clinical Trials
31 trialsEndoBARR
Medical College of Wisconsin
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
University of Colorado, Denver
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Memorial Sloan Kettering Cancer Center
ARIANES
Gustave Roussy, Cancer Campus, Grand Paris
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Memorial Sloan Kettering Cancer Center
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
University of Washington
PLATFORM
Royal Marsden NHS Foundation Trust
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Brown University
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
MAMOC
North Eastern German Society of Gynaecological Oncology
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
University of Kentucky
TRIUMPH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
University of Arizona
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Hoosier Cancer Research Network
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
ROAR
University of Utah
Clovis-001
University of Oklahoma
DRUP
The Netherlands Cancer Institute
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
Abramson Cancer Center at Penn Medicine
MiST
University of Leicester
RiME
University of Kansas Medical Center
MITO25
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RUBY
UNICANCER
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
University of Chicago
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
University of California, San Francisco
MaRuC
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Cancer Research UK